OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

Oxford Biomedica PLC ORD 50P/  GB00BDFBVT43  /

London Domestic
2024-04-26  5:48:48 PM Chg. +8.5000 Volume Bid2024-04-26 Ask5:49:35 PM Market Capitalization Dividend Y. P/E Ratio
228.5000GBX +3.86% 298,640
Turnover(GBP): 587,541.7153		 -Bid Size: - -Ask Size: - 182.73 mill.GBP - -
GlobeNewswire 04-01 Autolus Therapeutics Announces Changes to its Board of Directors
GlobeNewswire 03-18 Homology Medicines Declares Distribution to Common Stockholders
GlobeNewswire 03-06 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
GlobeNewswire 03-05 Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
GlobeNewswire 01-29 Oxford Biomedica completes acquisition of ABL Europe
GlobeNewswire 01-23 Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufac...
GlobeNewswire 01-07 Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical ...
GlobeNewswire 01-03 Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
GlobeNewswire 2023-12-07 Business Update
GlobeNewswire 2023-12-04 Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position...
GlobeNewswire 2023-11-16 Q32 Bio and Homology Medicines Announce Merger Agreement
GlobeNewswire 2023-11-14 Homology Medicines Reports Third Quarter 2023 Financial Results
GlobeNewswire 2023-11-09 Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire 2023-09-20 Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed...
GlobeNewswire 2023-09-20 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
GlobeNewswire 2023-09-07 Oxford Biomedica to host webinar showcasing the TetraVecta™ system
GlobeNewswire 2022-03-23 Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
GlobeNewswire 2022-03-17 Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Upda...
GlobeNewswire 2022-03-11 Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solution...
GlobeNewswire 2022-03-10 Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Cap...
GlobeNewswire 2022-01-31 Oxford Biomedica announces update to agreement with Sio Gene Therapies
GlobeNewswire 2022-01-31 Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosido...
GlobeNewswire 2022-01-28 Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ establ...
GlobeNewswire 2022-01-28 Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ establ...
GlobeNewswire 2022-01-17 John Dawson to retire from Oxford Biomedica